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ABSTRACT
Among the neuroendocrine neoplasia, the pancreatic somatostatin-
producing tumors are very rare. Usually functional, these tumors produce 
the somatostatinoma syndrome, which encompasses diabetes mellitus, 
diarrhea/steatorrhoea, and cholelithiasis. Other symptoms may include 
dyspepsia, weight loss, anemia, and hypochlorhydria. All theses symptoms 
are explained by the inhibitory actions of the somatostatin released by tumoral 
cells originated from pancreatic delta cells or endocrine cells of the digestive 
tract. The diagnosis is easy to overlook since these symptoms are commonly 
observed in other more common syndromes. Besides the clinical features, 
diagnosis is based on serum determination of somatostatin, and imaging 
exams, such as ultrasound, computer tomography and positron emission 
tomography. Pathologic examination is characterized by the positivity 
of immunohistochemical reaction for synaptophysin, chromogranin, and 
somatostatin. These tumors can be classified according to tumor size, mitotic 
index, neural or vascular invasion, and distant metastases. The authors 
describe the case of a 61-year-old female patient who sought medical care 
because of a 6-month history of watery diarrhea, weight loss, and depression. 
She was diagnosed with diabetes mellitus 3 years ago. Imaging examination 
revealed a tumoral mass of 4 cm in its longest axis in the topography of the 
head of the pancreas and calculous cholecistopathy. The patient’s clinical 
status was unfavorable for a surgical approach. She died after 20 days of 
hospitalization. The definitive diagnosis was achieved with the autopsy 
findings, which disclosed a pancreatic somatostatinoma.
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CASE REPORT
A 61-year-old female patient was brought 
to the hospital with a history of intermittent watery 
diarrhea for the past 6 months, which became 
constant during the last month. The diarrhea 
had no mucus, blood, or steatorrhea, nor was it 
accompanied by abdominal pain. She referred being 
previously obese and used to present constipation. 
During the last 4 years she had been showing 
discouragement and a progressive loss of appetite, 
starting progressive anhedonia, failing to seek 
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but was distended with multiple images compatible 
with calculi in its interior. The computed tomography 
(CT) examination of the abdomen confirmed the 
USG findings and was complemented with a slight 
ectasia of the common bile duct (which measured 
8 mm). This stressed that the pancreatic lesion 
had poorly defined limits, showing heterogeneous 
enhancement after the contrast medium injection, 
and the duct of Wirsung was somewhat dilated 
(Figures 1 and 2).
CT of the chest and brain, upper 
gastrointestinal endoscopy, and colonoscopy were 
normal. Others exams included: determination of 
serum B12 vitamin, folic acid, and TSH and free T4, 
which were normal. HIV, hepatitis B and C serologies 
were all negative. Determination of carcinoembrionic 
antigen (CEA) = 18 µg/L (reference value (RV) < 3 
µg/L), carbohydrate antigen 125 (CA 125) = 7.6 U/
mL (RV < 35 U/mL) and CA 19-9 = 14 U/mL (RV 
< 37 U/mL). Thus the patient was diagnosed with 
chronic diarrhea, cachexia, uncontrolled diabetes 
mellitus, depression, calculous cholecystitis, and 
a tumor mass in the pancreatic head topography. 
She progressed presenting continuous epigastric 
pain and fever. A urinary tract infection was 
diagnosed and treated with ceftriaxone. On the 
eighth day of hospitalization, laboratory tests 
changed with elevation of AST, ALT, AP and γGT 
serum determinations. Total blood count changed to 
leukocytosis with neutrophilia accompanied by a shift 
to the left. Surgical treatment was contraindicated 
considering the patient’s clinical status to a high-grade 
severity surgery: gastroduodenopancreatectomy. 
The patient presented a progressive decrease in 
the level of consciousness and died on the twentieth 
day of hospitalization.
medical aid, and avoiding socializing. Concomitantly 
she presented a weight loss of 50 kg, which was 
more pronounced over the last 6 months. More 
recently, she could barely sustain her own weight in 
the upright position due to muscle atrophy. Her past 
medical history included the diagnoses of diabetes 
mellitus and hypertension, and was taking captopril 
and glibenclamide irregularly, without accurate 
monitoring. She denied smoking and consumption of 
alcoholic beverages. She was receiving assistance 
from neighbors who brought her to the hospital.
The initial physical examination showed an ill-
looking patient, pale, cachectic (weight = 40.1 kg), 
height = 1.56 m, and body mass index (BMI) = 16.4. 
Blood pressure = 160/90 mm Hg, pulse rate was 
regular = 84 beats per minute, respiratory rate = 16 
respiratory movements per minute, axillary 
temperature 36 °C, room air oximetry = 97%, and 
capillary glucose = 458 mg/dL (reference value (RV); 
80-99 mg/dL). Physical examination of the lungs 
and heart was normal, and the abdomen was flaccid 
with tenderness on palpation of the hypogastrium 
(clinically interpreted as a full urinary bladder); 
intestinal sounds were normal and no other organ 
enlargement was noted. Initial laboratory work up is 
shown in Table 1.
The patient was initially treated with volume 
replacement of saline, the potassium imbalance 
was corrected, and captopril and insulin were 
prescribed. The diagnostic investigation comprised 
an abdominal ultrasonography (USG) examination 
that revealed the presence of a heterogeneous 
nodular formation, measuring 3.7 × 2.5 × 4.0 cm, 
which was evidenced on the topography of the head 
of the pancreas. The gallbladder presented a thin wall 
Table 1 – Admission laboratory workup
RV RV
Hemoglobin 13.6 12.3-15.3 g/dL Potassium 2.6 3.5-5.0 mEq/L
Hematocrit 41 36.0-45.0% Sodium 140 3.5-5.0 mEq/L
Leucocytes 7200 4.4-11.3 103/mm3 ALT 15 136-146 mEq/L
Bands 0 1-5% AST 24 9-36 U/L
Segmented 74 45-70% γGT 23 1-24 U/L
Eosinophils 0 1-4% AF 78 10-100 U/L
Basophils 0 0-2.5% Amylase 55 20-104 U/L
Lymphocytes 18 18-40% Lipase 18 30-118 U/L
Monocytes 8 2-9% Glucose 421 80-99 mg/dL
Platelets 226.103 150-400 × 103/mm3 HbA1c 16% <5.4%
Urea 15 10-50 mg/dL PT (INR) 1.18 1
Creatinine 0.5 0.4-1.3 mg/dL Cai+ 1.19 1.11-1.40 mmol/L
AF = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; Cai+ = ionized calcium; γGT = gamma-glutamyl 
transferase; HbA1c = glycated hemoglobin; INR = international normalized ratio; PT = prothrombin time; RV = reference value.
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was performed and is summarized in Table 2. This 
research showed tumor cells diffusely positive 
for somatostatin and chromogranin A, with a low 
proliferative rate (Ki-67 < 2%), which allowed 
the diagnosis of a well-differentiated pancreatic 
somatostatinoma (Figures 3 and 4).
A distended gallbladder with dark greenish 
external surface was observed with deposition of 
friable material surrounded by a thick collection of 
peritoneal fluid. Upon opening, the gallbladder wall 
was thick, and contained a thick biliary secretion 
and micro calculi. The microscopic examination 
evidenced autolysis, acute inflammatory infiltrate 
in the wall, and serositis. This histological picture 
was compatible with acute cholecystitis with 
cholelithiasis (Figure 5).
The common bile duct was dilated with a 
1.0 cm diameter. At opening of the duodenum, the 
duodenal papilla was preserved, without calculous 
impaction, and with normal bile output with the 
gallbladder expression (Figure 6).
The history of diarrhea and diabetes mellitus 
associated with the autopsy findings of cholelithiasis 
with acute cholecystitis allows the diagnosis of 
somatostatinoma syndrome.
The thoracic cavity showed congestion in 
both lungs. The right lung weighed 417.0 g (RV 
range = 360-570 g) and left lung 452.0 g (RV 
range = 325-480 g), with friable areas on digital 
pressure. Microscopic examination diagnosed 
bronchopneumonia, edema, and areas of diffuse 
alveolar damage (Figure 7).
Acute cholecystitis and bronchopneumonia 
with diffuse alveolar damage led to septic shock. 
Despite the long hospitalization stay, 
definitive diagnosis could not be done, which is why 
an autopsy was performed.
Autopsy Findings
The abdominal cavity showed adhesion 
between the stomach, gallbladder and duodenum, 
with serositis. The pancreas weighed 131.0 g 
(RV range = 60-135 g), had a tumor located in 
the head, which was nodular and circumscribed, 
measuring 4.0 cm in its longest axis. The mass 
was homogeneous showing well-defined contours 
without areas of necrosis and hemorrhage. 
Microscopically, the tumor cells were relatively 
uniform and round, with finely granular eosinophilic 
cytoplasm and a centrally located round nucleus, 
arranged in a trabecular or ribbon pattern, 
separated by delicate fibrovascular stroma. The 
histological findings were consistent with pancreatic 
endocrine tumor. The immunohistochemical study 
Figure 1 – Axial computed tomography of the abdomen in the arterial phase. A - Heterogeneous mass in the 
topography of the head of the pancreas (white arrows) and dilation of the common bile duct (black arrow); 
B - Dilation of the pancreatic duct (white arrow) and the common bile duct (black arrow).
Figure 2 – Axial computed tomography of the 
abdomen showing the heterogeneous mass in the 
topography of the head of the pancreas, a hydropic 
gallbladder surrounded by a thin liquid layer.
32
Autopsy and Case Reports 2013; 3(1): 29-37 Vianna PM, Ferreira CR, Campos FPF.
abdominal aorta showed calcified, not ulcerated, 
atherosclerosis, which was consistent with the 
previous systemic arterial hypertension diagnosis.
The remaining organs and tissues showed 
no significant alterations on gross and microscopic 
examination.
DISCUSSION
Somatostatin-producing neuroendocrine 
tumor is a rare neoplasm usually arising in the 
pancreas and duodenum. Since its first description 
in 1977,1,2 less than 200 cases have been reported 
in the literature up until 2008. The annual estimated 
incidence is 1 in 40 million, with the median age at 
onset of 54 years (range, 24-84 years).2-4
Microscopically, the kidneys showed acute tubular 
necrosis, which may have contributed to the final 
events.
The kidneys also showed benign 
nephrosclerosis. The heart weighed 334.0 g (RV 
range = 179-385 g) and showed the left ventricle 
wall with a mild concentric hypertrophy. The 
Table 2 – Immunohistochemical panel used for 
diagnosis
Antigen Result Antigen Result
Chromogranin A Positive Calcitonin Negative
Somatostatin Positive Gastrin Negative
ACTH Negative Glucagon Negative
PP Negative Serotonin Negative
Insulin Negative Ki-67 Positive (< 2%)
ACTH = Adrenocorticotropic hormone, PP = pancreatic polypeptide.
Figure 3 – A - Gross macroscopic view of the somatostatinoma located in the head of the pancreas - histological 
appearance of the pancreatic somatostatinoma; B - Panoramic photomicrography of the tumor showing the 
well circumscribed border (arrow) and the normal pancreatic parenchyma (HE – 25×); C - Photomicrography 
of the tumor cells arranged in a trabecular or ribbon pattern, separated by delicate fibrovascular stroma 
(HE – 100×); D - Photomicrography of tumor cells with a relatively uniform and round shape, with fine 
granular eosinophilic cytoplasm and a central located round nucleus (HE – 400×).
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weight loss, anemia, and hypochlorhydria.16 All 
these symptoms can be explained by the inhibitory 
actions of somatostatin in the release or action of 
insulin, glucagon, gastrin, secretin, somatotrophin, 
thyrotropin, gastric inhibitory peptide, vasoactive 
intestinal peptide (VIP), pancreatic polypeptide 
(PP), and cholecystokinin.16,17
The patient of this report presented chronic 
diarrhea, cachexia, diabetes mellitus, depression, 
and calculous cholecystitis, which could be 
considered as symptoms of typical somatostatinoma 
syndrome. However, these symptoms seemingly 
were not observed together during the diagnostic 
process, and the diagnosis of pancreatic 
somatostatinoma was not taken into consideration.
We suspected that the mood disorder 
(depression), which was probably a result of the 
pancreatic tumor, explained the delay in seeking 
medical attention. The unmotivated patient only 
sought treatment because she was being taken 
care of by neighbors, reaching the medical facility 
Somatostatinoma derive from the 
somatostatin-producing delta cells of the pancreas 
or the endocrine cells of the digestive tract5,6 and 
may be sporadic (93.1%) or familial (6.9%) in 
association with neurofibromatosis type 1 (NF1), 
multiple endocrine neoplasia type 1 (MEN1), 
and Von Hippel–Lindau syndromes.4,7-10 Most 
somatostatinomas (56%) originate in the pancreas 
and are usually functional. Extra-pancreatic 
somatostatinomas (44%) are located in the 
duodenum and occasionally in the biliary tract or 
small bowel.4,11-15
In most patients, these tumors are 
symptomatic, with variable nonspecific clinical 
presentation. Only a few patients may present with 
the typical clinical somatostatinoma syndrome, which 
consists of diabetes mellitus, diarrhea/steatorrhoea, 
and cholelithiasis. Somatostatinoma syndrome was 
described 2 years after the first somatostatinoma 
was reported by Krejs in 1979, being more 
common in pancreatic somatostatinomas than in 
the duodenal counterpart.16-18 Additional symptoms 
have been identified and include dyspepsia, 
Figure 4 – Immunohistochemical photomicrography of the tumor. A - Somatostatin positive (100×); 
B - Chromogranin A positive (100×); C - Insulin negative in the tumor cells but focal positivity in a Langerhans 
islet (arrow) in the non-neoplastic parenchyma (100×); D - Ki-67 positive (<2%) (200×).
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Figure 6 – A and B - Gross macroscopic examination of distended gallbladder and dilated common bile duct; 
C - Preserved duodenal papilla (arrow) with output of bile with the gallbladder expression.
Figure 7 – A - Gross macroscopic view of right lung showing congested lower lobe; B - Photomicrography of the 
pulmonary parenchyma showing edema and acute inflammatory infiltrate in the alveolar spaces and bronchus 
(HE – 100×); C - Area of diffuse alveolar damage with fibrin deposition in the alveolar lumen (HE – 100×).
Figure 5 – A and B - Gross macroscopic view of distended gallbladder with dark greenish and external 
surfaces, with deposition of friable material, surrounded by a thick collection; C - Photomicrography of the 
gallbladder showing evident autolysis and acute inflammatory infiltrate (HE – 25×); D - Photomicrography of 
the gallbladder wall showing, in detail, the acute inflammatory infiltrate (HE – 400×).
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Microscopically, the growth pattern can be solid, 
nested, trabecular, ribbon like, tubuloacinar, or 
glandular, and mixed patterns are common in the 
same tumor.27,28 Psammoma bodies are commonly 
observed in duodenum somatostatinoma, but 
rarely in the pancreas.29,30 Immunohistochemical 
stains for synaptophysin and chromogranin A 
typically show diffuse positivity. In most cases, the 
histologic pattern does not determine the functional 
status of the tumors.31 The accurate diagnosis of 
somatostatinoma depends on the intense positive 
immunohistochemical reaction for somatostatin32.
In the recent World Health Organization 
Classification of Tumours Pathology and Genetics 
of Tumours of Endocrine Organs, Heitz et al.27 
proposed criteria for the clinicopathological 
classification of pancreatic endocrine tumors. 
Well-differentiated tumors are divided into those 
with ‘‘benign’’ behavior and those with “uncertain” 
behavior. The tumors considered as benign include 
those confined to the pancreas that are non-
angioinvasive, without perineural invasion, and less 
than 2 cm in diameter, with fewer than 2 mitotic 
figures per 10 high-power fields and less than 
2% Ki-67-positive cells. The tumors of uncertain 
behavior include those confined to the pancreas 
with any of the following features: greater than or 
equal to 2 cm in diameter, 2-10 mitoses per 10 
high-power fields, greater than 2% Ki-67-positive 
cells, angioinvasion, or perineural invasion. Well-
differentiated endocrine carcinomas are diagnosed 
when there is local invasion or metastasis. Poorly 
differentiated endocrine carcinoma is diagnosed 
when there are more than 10 mitotic figures per 10 
high-power fields.27
The patient of this report had a tumor 
classified as a well-differentiated tumor with 
uncertain behavior as it had 4 cm on its longest 
axis and no metastases. Most somatostatinomas 
are malignant (71.2%), presenting metastases 
commonly in the liver, peripancreatic lymph nodes, 
and bone.3,33
Tumor size is a pertinent prognostic factor.4 
The diameter of 2 cm is considered the cut-off value, 
above which the risk of metastasis significantly 
increases.26,34 Indeed, by the time they are detected, 
nearly 30% of duodenal and 70% of pancreatic 
somatostatinomas have already metastasized to 
the regional lymph nodes or the liver.30
Treatment largely depends on the site and 
size of the tumor and the extent of the disease at the 
time of diagnosis.4 Surgical resection is the treatment 
of choice.35,36 In cases of locally advanced disease or 
presenting a debilitating nutritional status. During 
the diagnostic workup, the image of the tumor in the 
head of the pancreas added to the intense weight 
loss, probably led the surgeons to think of pancreatic 
adenocarcinoma. For a curative treatment, this 
would require a gastroduodenopancreatectomy, 
which represents a high-grade surgical procedure. 
As the patient was not clinically prepared for such a 
procedure, surgical treatment was disregarded.
USG is the most sensitive method to 
demonstrate somatostatinomas of pancreas and 
duodenum. The sensitivity of trans abdominal USG 
for detection varies from less than 20% to as high as 
80%.19-22 They appear as well circumscribed round 
or oval hypoechoic masses with smooth margins.
The CT and positron emission tomography 
(PET) images show circumscribed solid masses 
that tend to displace surrounding structures. 
Smaller lesions tend to be more homogeneous, 
and larger lesions are more likely to demonstrate 
heterogeneous enhancement, a finding due to 
areas of cystic degeneration, necrosis, fibrosis, 
and calcification.20 When contrast material is 
administered, they demonstrate a hyper-vascular 
pattern.23.
The diagnosis is confirmed by documentation 
of elevated plasma concentrations of somatostatin 
and the presence of the somatostatinoma syndrome. 
If the plasmatic basal levels of somatostatin do 
not indicate values at least three times the normal 
concentration, diagnostic tests, both stimulatory 
(with tolbutamide, calcium/pentagastrin, or 
secretin) and inhibitory (with diazoxide), can be 
performed.4,24,25 However, serum determination of 
somatostatin is often overlooked when patients 
present nonspecific symptoms, as it may happen 
with the somatostatinoma syndrome.
In the case presented here, if the 
somatostatinoma syndrome had been taken 
into account, the somatostatin could have been 
determined. In turn, and the correct diagnosis would 
have been made, what which possibly could have 
changed the adopted approach.
Pathological examination of the surgical 
specimen provides the definitive diagnosis. Grossly, 
somatostatinomas usually occur as solitary (up 
to 90%), are generally large by the time they 
are detected (average diameter, 5-6 cm in the 
pancreas and 2-5 cm in the duodenum), are well-
circumscribed, but not encapsulated, are soft, and 
nodules are gray-white to yellow-tan in color.1,4,26 
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widespread metastases, tumor debulking, chemo-
embolization of the primary tumor and of hepatic 
metastases, chemotherapy, somatostatin receptor 
subtype-selective (SSTR-analogs, octreotide), and 
interferon–alpha (IFN-α) can be used to control the 
clinical symptoms.37
CONCLUSION
Early detection of pancreatic somatostatinoma 
could be difficult, in part, by the rarity of the disease 
and the presence of variable symptoms. This 
case report not only presents the autopsy findings 
of a rare entity, but also alerts physicians to the 
importance of recognizing all symptoms as being 
part of a syndrome that is usually overlooked. In this 
case, if the correct diagnosis had been made in her 
lifetime, perhaps the patient would have benefited 
from surgical treatment.
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